An early Parkinson’s study follows movement, balance and thinking

Since the previous research note · Earlier expectation not tested

Track continuity

Since the previous research note: What do body-first and brain-first Parkinson’s labels reveal?

Previous expectation: Reproducible Parkinson’s trajectories could improve prognosis and help match participants to trials of treatments intended to slow disease.

What this study adds: NCT07187843 describes a further human observational investigation connecting proposed phenotypes with functional progression, imaging and biomarkers. Its supplied registry snapshot contains no posted results testing the earlier forecast.

---

What changed in this study

A Parkinson’s diagnosis raises practical questions that labels alone cannot answer. Will walking become less steady? Will turning, balance or getting up from a chair become harder? Could thinking changes follow a different course? A clinical study in Reggio Emilia, Italy, is designed to examine whether proposed Parkinson’s patterns are connected with those everyday difficulties over time.

The study focuses on people with early-stage Parkinson’s disease and is observational, meaning investigators will measure and compare participants rather than assign a treatment. The registry description identifies an estimated cohort of 150 people, detailed clinical assessments, imaging and blood-based measurements. Its publication date is September 23, 2025; the expanded record used here describes the study’s planned comparisons and measurements, not demonstrated differences between groups.

Why walking and thinking matter in daily life

Axial symptoms involve functions such as posture, gait and balance. They can affect how safely and independently a person moves through ordinary settings. Cognitive symptoms can also influence daily life, although the supplied study description does not specify a particular cognitive test or endpoint. The researchers identify both axial and cognitive progression as important areas of interest because they are major contributors to disability in Parkinson’s disease.

The question is therefore more specific than whether two groups look different at diagnosis. It asks whether a proposed biological pattern is associated with a different clinical course: changes in walking, turning, balance, falling risk or thinking as the years pass. That makes the study relevant to prognosis research while keeping the reader’s attention on observable functions rather than on labels alone.

Two proposed routes into Parkinson’s

The brain-first and body-first ideas describe hypotheses about where disease-related processes may begin and how they may spread. In the brain-first account, the process begins in the central nervous system and later involves the autonomic system. In the body-first account, it begins in peripheral structures, such as the enteric nervous system, and moves toward the brain.

The registry uses clinical and instrumental features to form comparison groups. People with early Parkinson’s disease without REM sleep behavior disorder are described as consistent with a brain-first phenotype. People whose REM sleep behavior disorder occurred before or at motor onset are described as consistent with a body-first phenotype, alongside instrumental findings. These rules help investigators organize the cohort, but they are not direct proof of where the disease process began in an individual.

That distinction matters because a useful research classification can be associated with a pattern without serving as a confirmed biological history. The study is testing whether the proposed grouping relates to later measurements, not simply declaring that every participant’s disease followed one proven route.

Following movement through five years

The planned follow-up makes the study’s central question tangible. Participants are assessed at baseline and at annual visits through 60 months. An instrumented Timed Up and Go test records several parts of movement, including standing up, sitting down, turning, walking forward and returning. It also measures the duration of movement phases and trunk acceleration in three directions.

The assessments are planned in medication-off and medication-on conditions, including single-task and dual-task versions. This gives the investigators several ways to examine how movement changes across time and under different testing conditions. A baseline comparison might show that groups start at different levels. Repeated measurements ask a harder question: do their paths diverge, converge or remain similar as follow-up continues?

The record also lists the Walking Handicap Scale, which ranges from limited walking ability to independent social ambulation. Scores can help describe walking function and community mobility. A scale score should not be confused with a count of actual falls, however. The study separately considers fall risk, while the supplied description does not authorize treating a risk measure as proof that one group experienced more falls.

Cognitive progression is another stated focus, but the available study description does not provide enough detail to name a cognitive instrument or invent a specific cognitive outcome. The appropriate conclusion at this stage is that thinking is part of the research question, while the registered details supplied here are clearest about movement and balance measurements.

What imaging and blood measurements contribute

Clinical tests show how a person is functioning. Imaging and blood measurements can add observations about biological features that may accompany those changes. The study plans neuroimaging and biomarker assessments related to neurodegeneration and neuroinflammation, creating an opportunity to examine whether clinical trajectories and biological measurements vary together.

The registry names neurofilament light as a neurodegeneration marker and also lists inflammatory measurements, including immune responses to α-synuclein, interferon-gamma and interleukin-5. The aim is to examine whether the proposed phenotypes differ in these biological measurements as well as in their clinical progression.

The expanded record describes biomarker work in a subset of 50 participants within the estimated 150-person cohort. That smaller group matters when interpreting the design. Clinical follow-up and biomarker analysis may not involve exactly the same number of people, so a biological association would need to be understood in the context of who was measured and how consistently measurements were collected.

What this design can tell us

The registry entry tells readers what the investigators intend to observe: proposed phenotype grouping, repeated movement and balance assessments, imaging and selected biological measurements. It does not establish which group will develop mobility or cognitive difficulties faster. It also does not establish that the grouping rule identifies the true starting location of disease in any one patient.

Even a difference that emerged during follow-up would first be an association between a classification, biological measurements and clinical change. It would need replication and broader testing before becoming a validated individual prognostic tool. It would also need a demonstrated connection to decisions that improve care before it could function as an actionable treatment-selection test. A listed study-completion date describes the study lifecycle; it is not itself evidence that analyzed results are available.

This is why the value of the project rests on more than finding a difference between two names. The important result would be a reproducible relationship that survives repeated assessment, biological scrutiny and testing beyond this single movement-disorders center. Until then, the study is best understood as a structured attempt to connect possible disease patterns with changes that matter in daily life.

What clearer Parkinson’s trajectories could mean for patients

If the links between proposed phenotype, biomarkers and later clinical course prove reproducible, clinicians could eventually have more useful conversations with patients about the kinds of mobility, balance or cognitive difficulties that may deserve attention. That would not mean predicting an individual’s future from one label. It would mean adding better-supported information to discussions that currently have to account for substantial variation between people.

The same evidence could help researchers group participants more carefully in trials intended to slow Parkinson’s disease. A trial may be easier to interpret when participants with meaningfully different biological and clinical trajectories are identified early. Matching treatment to disease biology is a further possibility, but it would require an actionable mechanism and demonstrated benefit, neither of which this study establishes.

For now, NCT07187843 marks a prospective step in testing whether proposed brain-first and body-first patterns correspond to measurable changes in walking, balance and thinking. Its importance will depend on what the longitudinal data show, how well the findings generalize, and whether they can support decisions that improve patients’ lives.

Key Sources

• Primary source: Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD
  Government or Regulator · Clinical Trial · 2025-09-23